Pre-existing resistance in the latent reservoir can compromise VRC01 therapy during chronic HIV-1 infection
Sign Up to like & getrecommendations! Published in 2020 at "PLoS Computational Biology"
DOI: 10.1371/journal.pcbi.1008434
Abstract: Passive immunization with broadly neutralizing antibodies (bNAbs) of HIV-1 appears a promising strategy for eliciting long-term HIV-1 remission. When administered concomitantly with the cessation of antiretroviral therapy (ART) to patients with established viremic control, bNAb… read more here.
Keywords: hiv; latent reservoir; resistance; therapy ... See more keywords
Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial
Sign Up to like & getrecommendations! Published in 2017 at "PLoS Medicine"
DOI: 10.1371/journal.pmed.1002435
Abstract: Background VRC01 is an HIV-1 CD4 binding site broadly neutralizing antibody (bnAb) that is active against a broad range of HIV-1 primary isolates in vitro and protects against simian-human immunodeficiency virus (SHIV) when delivered parenterally… read more here.
Keywords: administration; vrc01 administered; infusion; antibody ... See more keywords
Delayed vaginal SHIV infection in VRC01 and anti-α4β7 treated rhesus macaques
Sign Up to like & getrecommendations! Published in 2019 at "PLoS Pathogens"
DOI: 10.1371/journal.ppat.1007776
Abstract: VRC01 protects macaques from vaginal SHIV infection after a single high-dose challenge. Infusion of a simianized anti-α4β7 mAb (Rh-α4β7) just prior to, and during repeated vaginal exposures to SIVmac251 partially protected macaques from vaginal SIV… read more here.
Keywords: infection vrc01; shiv infection; infection; delayed vaginal ... See more keywords